Abuse-deterrent opioids: an update on current approaches and considerations

References

• Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016;374:154-63
   PubMed Web of Science ®Google Scholar
• Vacalis SE. Leave no patient behind - educating primary care providers on pain relief. Physicians Weekly 2016. Available online at: http://www.physiciansweekly.com/leave-no-patient-behind-educating-primary-care-providers-on-pain-relief/ [Last accessed 7 December 2016]
   Google Scholar
• Guy GP Jr, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697-704
   PubMed Web of Science ®Google Scholar
• Hughes A, Williams MR, Lipari RN, et al. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. NSDUH Data Review 2016:A1-A24
   Google Scholar
• Centers for Disease Control and Prevention. Prescription overdose data. Atlanta, GA; 2017. Available online at: https://www.cdc.gov/drugoverdose/data/overdose.html [Last accessed 29 September 2017]
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). In: Center for Behavioral Health Statistics and Quality: Substance Abuse and Mental Health Services Administration. Rockville, MD: HHS; 2017
   Google Scholar
• Alexander L, Weingarten B. A pharmacist’s guide to the emerging abuse deterrence technology used in opioid analgesics. Pharmacy Times 2014;17:1–16
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Abuse-deterrent opioids - evaluation and labeling: guidance for industry. Silver Spring, MD: US DoH; 2015
   Google Scholar
• Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J 2009;6:8
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Teti M, Silva K, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy 2012;23:37-44
   PubMed Web of Science ®Google Scholar
• Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend 2017;175:140-5
   PubMed Web of Science ®Google Scholar
• Hale ME, Moe D, Bond M, et al. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag 2016;6:497-508
   PubMed Web of Science ®Google Scholar
• Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10(Suppl 2):S124–33
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA News Release. FDA requests removal of Opana ER for risks related to abuse. 2017. Silver Spring, MD. Available online at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm [Last accessed 25 June 2017]
   Google Scholar
• Gottlieb S, Woodcock J. Marshaling FDA benefit-risk expertise to address the current opioid abuse epidemic. JAMA 2017;318:421-2
   PubMed Web of Science ®Google Scholar
• OxyContin (oxycodone hydrochloride) extended-release tablets [package insert]. Stamford (CT): Purdue Pharma L.P.; 2015
   Google Scholar
• Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol 2014;54:468-77
   PubMed Web of Science ®Google Scholar
• Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015;372:241-8
   PubMed Web of Science ®Google Scholar
• Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol 2013;27:808-16
   PubMed Web of Science ®Google Scholar
• Targiniq™ ER (oxycodone hydrochloride and naloxone hydrochloride) extended-release tablets [package insert]. Stamford (CT): Purdue Pharma L.P.; 2016
   Google Scholar
• Troxyca® ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules [package insert]. New York (NY): Pfizer, Inc.; 2016
   Google Scholar
• Setnik B, Bass A, Bramson C, et al. Abuse potential study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) compared with immediate-release oxycodone administered orally to nondependent recreational opioid users. Pain Med 2017;18:1077-88
   PubMed Web of Science ®Google Scholar
• Setnik B, Bramson C, Bass A, et al. Intranasal administration of crushed ALO-02 (extended-release oxycodone with sequestered naltrexone): a randomized, controlled abuse-potential study in nondependent recreational opioid users. J Clin Pharmacol 2015;55:1351-61
   PubMed Web of Science ®Google Scholar
• Backonja M, Webster LR, Setnik B, et al. Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. Am J Drug Alcohol Abuse 2016;42:539-49
   PubMed Web of Science ®Google Scholar
• Xtampza® ER (oxycodone) extended-release capsules [package insert]. Canton (MA): Collegium Pharmaceutical, Inc.; 2016
   Google Scholar
• Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med 2015;16:2142-51
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Levy-Cooperman N, et al. Oral human abuse potential of oxycodone DETERx(R) (Xtampza(R) ER). J Clin Pharmacol 2017;57:500-12
   PubMed Web of Science ®Google Scholar
• Kopecky EA, Fleming AB, Noonan PK, et al. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx(R): an extended-release, abuse-deterrent formulation. J Opioid Manag 2014;10:233-46
   PubMedGoogle Scholar
• Webster LR, Kopecky EA, Smith MD, et al. A randomized, double-blind, double-dummy study to evaluate the intranasal human abuse potential and pharmacokinetics of a novel extended-release abuse-deterrent formulation of oxycodone. Pain Med 2016;17:1112-30
   PubMed Web of Science ®Google Scholar
• RoxyBond™ (oxycodone hydrochloride) tablets [package insert]. Morristown, NJ: Inspirion Delivery Sciences, LLC; 2017
   Google Scholar
• Hysingla™ ER (hydrocodone bitartrate) extended-release tablets [package insert]. Stamford (CT): Purdue Pharma L.P.; 2014
   Google Scholar
• Harris SC, Cipriano A, Colucci SV, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med 2017;18:1278-91
   PubMed Web of Science ®Google Scholar
• Harris SC, Cipriano A, Colucci SV, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med 2016;17:820-31
   PubMed Web of Science ®Google Scholar
• Vantrela™ ER package insert (hydrocodone bitartrate) extended-release tablets [package insert]. North Wales, PA: Teva Pharmaceuticals; 2017
   Google Scholar
• Farber R, Rae S. This week in FDA vs Biotech Part I, will Teva’s Vantrela get abuse-deterrent label? Market Exclusive: Weekly Biotech Report; 2016. Available online at: https://marketexclusive.com/weeklybiotechreportcoveringvantrela/ [Last accessed 26 June 2017]
   Google Scholar
• Darwish M, Bond M, Ma Y, et al. Abuse potential with oral route of administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Pain Med 2017;18:61-77
   PubMed Web of Science ®Google Scholar
• Arymo ER (morphine sulfate) extended-release tablets [package insert]. Wayne (PA): Egalet Corporation; 2017
   Google Scholar
• Smith MD, Webster LR, Lawler J, et al. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) versus extended-release morphine administered orally in nondependent recreational opioid users. Pain Med 2017;18:898-907
   PubMed Web of Science ®Google Scholar
• Webster LR, Smith MD, Lawler J, et al. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (morphine-ADER injection-molded tablets) vs extended-release morphine administered intranasally in nondependent recreational opioid users. Pain Med 2017;18:1695-1705
   PubMed Web of Science ®Google Scholar
• Embeda® (morphine sulfate and naltrexone hydrochloride) extended-release capsules [package insert]. New York (NY): Pfizer Inc; 2014
   Google Scholar
• Setnik B, Goli V, Levy-Cooperman N, et al. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag 2013;18:e55-62
   PubMed Web of Science ®Google Scholar
• Setnik B, Roland CL, Goli V, et al. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. J Opioid Manag 2013;9:139-50
   PubMedGoogle Scholar
• Setnik B, Sommerville K, Goli V, et al. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. Pain Med 2013;14:1173-86
   PubMed Web of Science ®Google Scholar
• Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29:777-90
   PubMed Web of Science ®Google Scholar
• Webster LR, Johnson FK, Stauffer J, et al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D 2011;11:259-75
   PubMedGoogle Scholar
• MorphaBond™ ER (morphine sulfate) extended-release tablets [package insert]. Basking Ridge (NJ): Daiichi Sankyo, Inc.; 2017
   Google Scholar
• Webster LR, Pantaleon C, Shah MS, et al. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine-morphine ARER. Pain Med 2017;18:1303-13
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. MorphaBond new drug application: Clinical pharmacology and biopharmaceutics review; 2015. Silver Spring, MD. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206544Orig1s000ClinPharmR.pdf
   Google Scholar
• Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther 2016;100:275-86
   PubMed Web of Science ®Google Scholar
• Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf 2013;22:1274-82
   PubMed Web of Science ®Google Scholar
• Severtson SG, Ellis MS, Kurtz SP, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend 2016;168:219-29
   PubMed Web of Science ®Google Scholar
• Sessler NE, Downing JM, Kale H, et al. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf 2014;23:1238-46
   PubMed Web of Science ®Google Scholar
• Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ 2014;17:279-87
   PubMedGoogle Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14:351-8
   PubMed Web of Science ®Google Scholar
• Chilcoat HD, Coplan PM, Harikrishnan V, et al. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin). Drug Alcohol Depend 2016;165:221-8
   PubMed Web of Science ®Google Scholar
• Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain 2013;14:1122-30
   PubMed Web of Science ®Google Scholar
• Jones CM, Muhuri PK, Lurie PG. Trends in the nonmedical use of OxyContin, United States, 2006 to 2013. Clin J Pain 2017;33:452-61
   PubMed Web of Science ®Google Scholar
• Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin. JAMA Psychiatry 2015;72:424-30
   PubMed Web of Science ®Google Scholar
• Simon K, Worthy SL, Barnes MC, et al. Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Ther Adv Drug Saf 2015;6:67-79
   PubMedGoogle Scholar
• White A, Yenikomshian M, Carson M, et al. A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids. J Pain 2016;17(suppl):S41
   Google Scholar
• Kirson NY, Shei A, White AG, et al. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med 2014;15:1450-4
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Abuse-deterrent opioids: final evidence report. 2017. Boston, MA. Available online at: https://icer-review.org/material/adf-final-report/ [Last accessed 27 November 2017]
   Google Scholar
• Keast SL, Owora A, Nesser N, et al. Evaluation of abuse-deterrent or tamper-resistant opioid formulations on overall health care expenditures in a state Medicaid program. J Manag Care Spec Pharm 2016;22:347-56
   PubMed Web of Science ®Google Scholar
• Skinner BJ. Societal cost savings from abuse deterrent formulations for prescription opioids in Canada. Canadian Health Policy; 2017. Toronto, Ontario, Canada. Available online at: www.canadianhealthpolicy.com [Last accessed 27 November 2017]
   Google Scholar
• Wiedemer NL, Harden PS, Arndt IO, et al. The opioid renewal clinic: a primary care, managed approach to opioid therapy in chronic pain patients at risk for substance abuse. Pain Med 2007;8:573-84
   PubMed Web of Science ®Google Scholar
• American Medical Association. AMA education center. AMA; 2017. Chicago, IL [Last accessed 27 November 2017]. Available online at: https://cme.ama-assn.org/Activity/4896593/Detail.aspx
   Google Scholar
• Iwanicki JL, Severtson SG, McDaniel H, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS One 2016;11:e0167499
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC guideline for prescribing opioids for chronic pain - United States. MMWR Recomm Rep 2016;65:1-49
   Web of Science ®Google Scholar
• American Medical Association. AMA wire: what phsyicians are saying about the new CDC opioid guidelines. AMA; 2016. Chicago, IL [Last accessed 27 November 2017]. Available online at: https://wire.ama-assn.org/delivering-care/what-physicians-are-saying-about-new-cdc-opioid-guidelines
   Google Scholar
• Coplan PM, Kadakia A. Changes in diagnosed addiction rates in patients prescribed OxyContin (ERO) or other opioids after introduction of ERO with abuse-deterrent properties. Pharmacoepidemiol Drug Saf 2015;24:27. Abstract 46
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Zhang F, Ross-Degnan D, et al. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene. JAMA Intern Med 2015;175:978-87
   PubMed Web of Science ®Google Scholar
• Michna E, Kirson NY, Shei A, et al. Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin 2014;30:1589-98
   PubMed Web of Science ®Google Scholar
• Cassidy TA, DasMahapatra P, Black RA, et al. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med 2014;15:440-51
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bruno R, Ali R, et al. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. Drug Alcohol Depend 2015;151:56-67
   PubMed Web of Science ®Google Scholar
• Pezalla EJ, Rosen D, Erensen JG, et al. Secular trends in opioid prescribing in the USA. J Pain Res 2017;10:383-7
   PubMed Web of Science ®Google Scholar